Pharming Group N.V.

PHARM

NL0010391025

Pharmaceuticals

Real-time Euronext Amsterdam Other stock markets 03:11:51 2024-04-23 am EDT			5-day change	1st Jan Change
0.908 ^EUR	+0.89%		-5.56%	-11.93%

Apr. 22	Pharming Group to Buy Back EUR123 Million of Bonds due 2025	MT
Apr. 18	Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds	MT

Pharming Group N.V. Provides Earnings Guidance for the Year 2021

October 28, 2021 at 01:00 am EDT

Pharming Group N.V. provided earnings guidance for the year 2021. For the period, the company expects Maintenance of positive net earnings during the remainder of the year.

Latest news about Pharming Group N.V.

Pharming Group to Buy Back EUR123 Million of Bonds due 2025	Apr. 22	MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds	Apr. 18	MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding	Apr. 17	CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib	Apr. 08	CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder	Apr. 08	MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024	Mar. 14	CI
Pharming Group Seeks Acquisitions	Mar. 14	CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating	Jan. 09	MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies	Dec. 15	CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024	Dec. 13	MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA	Dec. 13	MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment	Nov. 10	MT
Transcript : Pharming Group N.V., Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director	23-09-25	CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call	23-09-25
ADRs Advance, Warrantee Inc. Climbs 20.0%	23-09-22	DJ
ADRs Close Lower; Quantasing Group Ltd. Declines 33.5%	23-09-21	DJ
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan	23-08-09	CI
Pharming Seeks Acquisitions	23-08-03	CI
Transcript : Pharming Group N.V., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Pharming Group N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9 EUR

Average target price

2 EUR

Spread / Average Target

+122.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMING GROUP N.V.	-11.93%	645M
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+25.38%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ABBVIE INC.	+8.34%	297B
ASTRAZENECA PLC	+6.13%	215B
NOVARTIS AG	+2.93%	210B
ROCHE HOLDING AG	-7.65%	200B
PFIZER, INC.	-8.79%	149B

Other Pharmaceuticals